Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Genitourinary Cancer

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes

Ann Oncol

Olmos D, Lorente D, Jambrina A, Tello Velasco D, Ovejero-Sánchez M, Gonzalez-Ginel I, Romero-Laorden N, Nunes-Carneiro D, Balongo M, Gutierrez-Pecharromán AM, Llácer C, Prieto JD, Pérez-Argüelles D, Alberca Del Arco F, Miguel-Masiá J, Ruiz-Vico M, Santos R, Esteban-Villarrubia J, Gonzalez-Billalabeitia E, Jürgens A, Capone C, Trevisan M, Van Sanden S, Stulnig G, Hernández D, López-Casas PP, A Rodriguez-Antolin, Castellano DE, Herrera-Imbroda B, Castro E

doi: 10.1016/j.annonc.2025.05.534

Genitourinary Cancer

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial

Lancet Oncol

Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Chang J, Healy CG, Niyazov A, Agarwal N

doi: 10.1016/S1470-2045(25)00031-2

Genitourinary Cancer

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer

Adv Ther

Bilen MA, Burbage S, Rossi C, Khilfeh I, Diaz L, Wang Y, Pilon D, Brown G, Shore N, Lowentritt B, Lin DW

doi: 10.1007/s12325-025-03270-z

Genitourinary Cancer

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

Eur Urol Oncol

Wallis CJD, Ekberg S, Morgans AK, Boegemann M, Paracha N, Gallagher E, Crowther MJ, Shore N

doi: 10.1016/j.euo.2025.03.001

Genitourinary Cancer

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)

Ann Oncol

Lin HM, Scheinberg T, Portman N, Kim RMN, Mellor R, Hunyh K, Faulkner AN, Mellett NA, Davis ID, Martin A, Sullivan D, Joshua A, McJannett M, Subhash V, Yip S, Azad AA, Marschner IC, North SA, McDermott RS, Chi KN, Stockler MR, Sweeney CJ, Meikle PJ, Horvath LG

doi: 10.1016/j.annonc.2025.05.529

Genitourinary Cancer

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review

JAMA Oncol

Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F

doi: 10.1001/jamaoncol.2024.0591

Genitourinary Cancer

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Eur Urol

Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ

doi: 10.1016/j.eururo.2024.08.021

Genitourinary Cancer

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Prostate

Shimomura T, Otsuka N, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Yamada H, Miki J, Kimura T, JIKEI YAYOI Collaborative Group

doi: 10.1002/pros.24885

Genitourinary Cancer

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Prostate

Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O

doi: 10.1002/pros.24855

Related content

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer